Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347966 | 0.91 | OTUD7B (0.43) | CRBNOTUD7BOPRD1OPRK1CHRNB2 | |
| SCHEMBL21233508 | 0.83 | JAK2 (0.40) | OTUD7BCYP1A2LTA4HGRIN1GRIN2A | |
| SCHEMBL2728185 | 0.81 | OTUD7B (0.38) | CRBNOTUD7BLTA4HSPRGRIN1 | |
| SCHEMBL19852843 | 0.79 | OTUD7B (0.42) | CRBNOTUD7BCYP1A2CHRNB2CHRNA3 | |
| SCHEMBL22958823 | 0.78 | OTUD7B (0.34) | CRBNOTUD7BCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL9963244 | 0.78 | OTUD7B (0.38) | OTUD7BOPRD1OPRK1LTA4HGRIN1 | |
| SCHEMBL21224568 | 0.76 | OTUD7B (0.37) | CRBNOTUD7BLTA4HSPRGRIN1 | |
| SCHEMBL24339013 | 0.75 | OTUD7B (0.38) | CRBNOTUD7BSPRCCNCCDK8 | |
| SCHEMBL2020246 | 0.75 | CCNC (0.44) | CRBNCCNCCDK8HPGD | |
| SCHEMBL2605421 | 0.75 | OTUD7B (0.41) | OTUD7BLTA4HGRIN1GRIN2ACCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204031-B | Spiro-lactam NMDA receptor modulators and uses thereof | 元羿生物科技(香港)有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-11 | — | — | US | disclosed |
| EP-3746447-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152687-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152687-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2B | CRBN 3025/4885OTUD7B 3145/4885CYP1A2 3961/4885 |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CRBN 3025/4885OTUD7B 3145/4885CYP1A2 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.